Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports encouraging results for 2013

Boehringer Ingelheim reports encouraging results for 2013

16th April 2014

Boehringer Ingelheim has announced its financial results for the 2013 business year, during which it generated a net sales of around 14.1 billion euros (11.62 billion pounds).

This represented a year-on-year increase of 1.4 per cent on a currency-adjusted basis and resulted in a 2.4 percentage point improvement in the return on net sales to 15 percent. The company was also able to increase its operating income despite challenging market conditions.

During the year, Boehringer Ingelheim was able to enter the oncology market for the first time and expand the size of its global workforce by three percent, while working on 90 research and development projects.

Its novel oral anticoagulant Pradaxa also continued to be a key driver of growth and has now been approved in more than 100 countries.

In the next two years alone, the firm is planning more than ten new launches spanning eight indications.

Professor Andreas Barner, chairman of the board of managing directors of Boehringer Ingelheim, said: "We expect to achieve net sales for our company in 2014 that are comparable to those in the previous year."ADNFCR-8000103-ID-801713087-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.